Moderna Stock Soars 177%: Why Analysts Are Still Split on What Comes Next
The Moderna stock surge sent shares up 177% on Wednesday, closing at $174.38, right after Moderna and Merck said their personalized melanoma vaccine hit its main goal in a Phase 3 trial, and yet Wall Street still isnโt fully on board about what this Moderna stock surge really means. This Moderna stock surge moved the Moderna stock price by tens of billions of dollars in a single session, but it also split the Moderna stock forecast into two very different camps, one side that sees the Moderna cancer vaccine as the start of something big, and another that thinks the rally already ran too far too fast.
Also Read: Micron Stock vs. SK Hynix: Which AI Chip Stock Will Surge More?
Moderna Stock Surge: Melanoma Vaccine Boosts Price And Forecast
What The Trial Actually Showed
The trial enrolled 1,137 patients with stage 2b to 4 melanoma, and every one of them had already had their tumor removed through surgery before joining. Volunteers got either up to nine doses of the personalized vaccine plus Keytruda, or just Keytruda on its own, for about a year. Patients on the combination lived longer without their melanoma coming back, and the treatment also cut the risk of the cancer spreading to other parts of the body, so it hit both the main goal and the secondary one. The companies didnโt flag any new safety issues, and this melanoma vaccine data is exactly what set off the debate thatโs now playing out among analysts.
